Opthea Limited OPT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
22/100
Weak

Ranked against 712 peers in Biotechnology

Key strengths

  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.78), with robust interest coverage.
  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.82), suggesting sticky customer base.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 18.3th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 0th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
7
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where OPT ranks in Biotechnology

Opthea Limited ranks #586 of 713 scored companies in Biotechnology by moat score — the top 82%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
582 INmune Bio Inc. INMB 22/100 Weak
583 Alaunos Therapeutics, Inc. TCRT 22/100 Weak
584 Indaptus Therapeutics, Inc. INDP 22/100 Weak
585 Silence Therapeutics Plc - Amer SLN 22/100 Weak
586 Opthea Limited OPT 22/100 Weak
587 Klotho Neurosciences, Inc. KLTO 22/100 Weak
588 Protagenic Therapeutics, Inc. PTIX 22/100 Weak
589 Protagenic Therapeutics, Inc. Warrant PTIXW 22/100 Weak
590 CalciMedica, Inc. CALC 22/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How OPT scores on the Corporate Default defenses

Pricing Power

Score 6 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 4 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 36 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 18 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 50 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 8 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding OPT's moat

What is Opthea Limited's moat score?

Opthea Limited (OPT) scores 22 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #586 of 713 scored companies in Biotechnology, the top 82%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (50/100) and its weakest is Cost Advantage (4/100).

How does Opthea Limited compare with other Biotechnology companies?

Opthea Limited ranks #586 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Silence Therapeutics Plc - Amer (SLN) at 22 just above it and Klotho Neurosciences, Inc. (KLTO) at 22 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Opthea Limited scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Opthea Limited?

The Corporate Default template measures 6 defenses, and OPT scores: Pricing Power (6), Cost Advantage (4), Customer Stickiness (36), Capital Efficiency (18), Resilience (50), Scale & Market Position (8). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000